Real-World Data Confirm Talazoparib Clinical Benefit in HER2-Negative, Advanced Breast Cancer
Patients with HER2-negative, locally advanced or metastatic breast cancer have experienced improved survival rates both in real-world data and the phase 3 EMBRACA trial.
Adjuvant Neratinib Does Not Improve Overall Survival in Glioblastoma, Yet May Offer Benefit for EGFR+ Subset
Although adjuvant neratinib was not found to improve progression-free or overall survival across a population of patients with glioblastoma, the agent yielded promising progression-free survival rates in a subset of patients with EGFR-positive disease.
Imatinib/Binimetinib Combo Shows Promising Responses in Treatment-Naïve GIST
Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.
Secondary Cytoreductive Surgery Only Offers Benefit to Select Patients With Ovarian Cancer
An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.
Frontline Pembrolizumab Plus Chemo Does Not Show Superior OS Over Chemo Alone in PD-L1+ Gastric/GEJ Adenocarcinoma
Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.
Ibrutinib/Rituximab Combo May Be an Effective Chemo-Free Therapy for Older Patients With MCL
Ibrutinib plus rituximab is effective, easy to administer, and removes the need for chemotherapy in older patients, say experts.
Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL
A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.
Cilta-cel May Be Superior Therapy in Triple-Class Relapsed/Refractory Myeloma
In comparison to physicians’ choice of treatment, ciltacabtagene autoleucel demonstrated significant advantages in progression-free and overall survival, time to next treatment, and overall response rate.
Trilaciclib May Alleviate Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer
Trilaciclib was associated with reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with a subtype of lung cancer.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512